GlassScriptPhysician profile
Linda S Katz
NPI 1841254802
$1,193.33
in general payments reported to CMS, 2019-2025
19 companies · $84.35 in 2025
The $84.35 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $96.81 · 2021: $216 · 2022: $305 · 2023: $150 · 2024: $192 · 2025: $84.35.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $426.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $611.12 | 2019-2024 | |
| Hologic Sales and Service, LLC | $89.12 | 2022-2025 | Myosure Tissue Removal Device, Aptima, Omni Hysteroscope |
| Gynesonics, INC. | $80.12 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Coopersurgical, INC. | $56.41 | 2019-2023 | Paragard T 380a |
| Merck Sharp & Dohme LLC | $44.71 | 2019-2021 | |
| Exeltis, USA INC. | $40.36 | 2024-2025 | Slynd |
| Agile Therapeutics, INC. | $36.22 | 2021-2022 | |
| Allergan, INC. | $28.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.70 | 2025 | |
| Avion Pharmaceuticals | $25.28 | 2020-2021 | |
| Astellas Pharma US INC | $24.91 | 2024 | Veozah |
| Medicem INC. | $24.25 | 2020 | |
| Pfizer INC. | $23.34 | 2022 | |
| Medtronic, INC. | $22.66 | 2023 | Truclear |
| Therapeuticsmd, INC. | $18.36 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $15.91 | 2025 | Wegovy |
| Minerva Surgical, INC | $13.01 | 2023 | |
| Vertical Pharmaceuticals, LLC | $11.57 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$2.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.